LALPATHLAB Dr. Lal Path Labs Q1 FY26 results (Apr–Jun 2025) and concall
Dr Lal Pathlabs delivered a robust Q1 FY26 performance characterized by double-digit growth in revenue and significant bottom-line expansion. The company is successfully driving premiumization through its SwasthFit portfolio and high-complexity testing, while maintaining a calibrated pricing strategy. Management remains focused on geographic expansion in the West and South and expects a recovery in the Suburban brand following a major IT stack transition.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 660 | 597 | 603 | 670 |
| EBITDA | 202 | 154 | 169 | 192 |
| Net profit | 131 | 98 | 156 | 134 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
